Clinical applications of optical coherence tomography in the posterior pole: The 2011 José Manuel Espino Lecture - Part II

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 2181-2206

  Arevalo, J Fernando ^a,b   Lasave, Andres F ^c   Arias, Juan D ^c   Serrano, Martin A ^c   Arevalo, Fernando A ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^c Clinica Oftalmologica Centro Caracas   (Venezuela)

Author keywords

AMD; DME; Retinal diseases; Spectral domain

Indexed keywords

RANIBIZUMAB;

BRANCH RETINAL ARTERY OCCLUSION; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CENTRAL SEROUS RETINOPATHY; CLINICAL EVALUATION; CLINICAL FEATURE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUSEN; EPIRETINAL MEMBRANE; EYE DISEASE; GEOGRAPHIC ATROPHY; HUMAN; IMAGE ANALYSIS; LAMELLAR MACULAR HOLE; LOW LEVEL LASER THERAPY; MACULAR PSEUDOHOLE; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PIGMENT EPITHELIUM; POSTERIOR POLE DISEASE; PROGNOSIS; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA HOLE; RETINA NEOVASCULARIZATION; RETINAL TELANGIECTASIA; RETINOSCHISIS; REVIEW; SUBRETINAL NEOVASCULARIZATION; VITREOMACULAR ADHESION; VITREOMACULAR TRACTION SYNDROME;

EID: 84887263459     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S51158     Document Type: Review

References (108)

1. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127(6): 688-693.
2. Mylonas G, Bolz M, Kriechbaum K, et al. Retinal architecture recovery after grid photocoagulation in diabetic macular edema observed in vivo by spectral domain optical coherence tomography. Retina. 2013;33(4):717-725.
3. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920-927.
4. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121(1):57-61.
5. Hannouche RZ, Avila MP, Isaac DL, Silva RS, Rassi AR. Correlation between central subfield thickness, visual acuity and structural changes in diabetic macular edema. Arq Bras Oftalmol. 2012;75(3):183-187.
6. Shimura M, Yasuda K, Yasuda M, Nakazawa T. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema. Retina. 2013;33(4):740-747.
7. Ito S, Miyamoto N, Ishida K, Kurimoto Y. Association between external limiting membrane status and visual acuity in diabetic macular oedema. Br J Ophthalmol. 2013;97(2):228-232.
8. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-943.
9. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144(5):741-746.
10. Robison CD, Krebs I, Binder S, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol. 2009;148(1):79-82. e2.
11. Yi K, Mujat M, Park BH, et al. Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in non-neovascular age-related macular degeneration. Br J Ophthalmol. 2009;93(2):176-181.
12. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology. 1996;103(8):1260-1270.
13. Friedman SM, Margo CE. Choroidal neovascular membranes: reproducibility of angiographic interpretation. Am J Ophthalmol. 2000;130(6): 839-841.
14. van Velthoven ME, de Smet MD, Schlingemann RO, Magnani M, Verbraak FD. Added value of OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT. Graefes Arch Clin Exp Ophthalmol. 2006;244(9):1119-1123.
15. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566-583.
16. Zhang N, Hoffmeyer GC, Young ES, et al. Optical coherence tomography reader agreement in neovascular age-related macular degeneration. Am J Ophthalmol. 2007;144(1):37-44.
17. Krebs I, Ansari-Shahrezaei S, Goll A, Binder S. Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol. 2008;246(6):811-815.
18. Malamos P, Sacu S, Georgopoulos M, Kiss C, Pruente C, Schmidt-Erfurth U. Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration. Invest Ophthalmol Vis Sci. 2009;50(10):4926-4933.
19. Chong EW, Wong TY, Kreis AJ, Simpson JA, Guymer RH. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ. 2007;335(7623):755.
20. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-1436.
21. Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol. 1973;90(3):206-217.
22. Davis MD, Gangnon RE, Lee LY, et al; Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report no 17. Arch Ophthalmol. 2005;123(11):1484-1498.
23. Ferris FL, Davis MD, Clemons TE, et al; Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS report no 18. Arch Ophthalmol. 2005;123(11):1570-1574.
24. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114(2):253-262.
25. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137(3):486-495.
26. Sarks SH. Drusen patterns predisposing to geographic atrophy of the retinal pigment epithelium. Aust J Ophthalmol. 1982;10(2):91-97.
27. Sebag M, Peli E, Lahav M. Image analysis of changes in drusen area. Acta Ophthalmol (Copenh). 1991;69(5):603-610.
28. Wang JJ, Foran S, Smith W, Mitchell P. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol. 2003;121(5): 658-663.
29. Green WR, Enger C. Age-related macular degeneration histopathologic studies. The 1992Lorenz E. Zimmerman Lecture. Retina. 1993;100(10):1519-1535.
30. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology. 2002;109(10):1767-1779.
31. Bressler NM, Munoz B, Maguire MG, et al. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. Arch Ophthalmol. 1995;113(3):301-308.
32. Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol. 1985;69(6):397-403.
33. Hartnett ME, Weiter JJ, Garsd A, Jalkh AE. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol. 1992;230(1):11-19.
34. Pauleikhoff D, Löffert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002;240(7):533-538.
35. Coscas F, Coscas G, Souied E, Tick S, Soubrane G. Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2007;144(4):592-599.
36. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001;132(5):668-681.
37. Spraul CW, Grossniklaus HE. Characteristics of Drusen and Bruch's membrane in postmortem eyes with age-related macular degeneration. Arch Ophthalmol. 1997;115(2):267-273.
38. Roquet W, Roudot-Thoraval F, Coscas G, Soubrane G. Clinical features of drusenoid pigment epithelial detachment in age related macular degeneration. Br J Ophthalmol. 2004;88(5):638-642.
39. Cukras C, Agrón E, Klein ML, et al; Age-Related Eye Disease Study Research Group. Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: age-related eye disease study report no 28. Ophthalmology. 2010;117(3):489-499.
40. Querques G, Bux AV, Delle Noci N. Foveal geographic atrophy following intravitreal pegaptanib sodium (Macugen) for drusenoid pigment epithelium detachment. Eur J Ophthalmol. 2009;19(5):890-893.
41. Krishnan R, Lochhead J. Regression of soft drusen and drusenoid pigment epithelial detachment following intravitreal anti-vascular endothelial growth factor therapy. Can J Ophthalmol. 2010;45(1):83-84.
42. Gallego-Pinazo R, Marina A, Suelves-Cogollos, et al. Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration. Clin Ophthalmol. 2011;5:161-165.
43. Yannuzzi LA, Hope-Ross M, Slakter JS, et al. Analysis of vascularized pigment epithelial detachments using indocyanine green videoangiography. Retina. 1994;14(2):99-113.
44. Cho M, Athanikar A, Paccione J, Wald KJ. Optical coherence tomography features of acute central serous chorioretinopathy versus neovascular age-related macular degeneration. Br J Ophthalmol. 2010;94(5):597-599.
45. Bressler SB, Silva JC, Bressler NM, Alexander J, Green WR. Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol. 1992;110(6):827-832.
46. Ting TD, Oh M, Cox TA, Meyer CH, Toth CA. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol. 2002;120(6):731-737.
47. Ozawa S, Ishikawa K, Ito Y, et al. Differences in macular morphology between polypoidal choroidal vasculopathy and exudative age-related macular degeneration detected by optical coherence tomography. Retina. 2009;29(6):793-802.
48. Lambert HM, Capone A Jr, Aaberg TM, Sternberg P Jr, Mandell BA, Lopez PF. Surgical excision of subfoveal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1992;113(3): 257-262.
49. Weber-Krause B, Eckardt U. Incidence of posterior vitreous detachment in eyes with and without age-related macular degeneration. An ultrasonic study. Ophthalmologe. 1996;93(6):660-665. German.
50. Ondes, F, Yilmaz G, Acar MA, Unlü N, Kocaoǧlan H, Arsan AK. Role of the vitreous in age-related macular degeneration. Jpn J Ophthalmol. 2000;44(1):91-93.
51. Mojana F, Cheng L, Bartsch DU, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146(2):218-227.
52. Quaranta-El Maftouhi M, Mauget-Faÿsse M. Anomalous vitreoretinal adhesions in patients with exudative age-related macular degeneration: an OCT study. Eur J Ophthalmol. 2006;16(1):134-137.
53. Toth CA, Birngruber R, Boppart SA, et al. Argon laser retinal lesions evaluated in vivo by optical coherence tomography. Am J Ophthalmol. 1997;123(2):188-198.
54. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
55. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144(6): 850-857.
56. Krebs I, Hagen S, Brannath W, et al. Repeatability and reproducibility of retinal thickness measurements by optical coherence tomography in age-related macular degeneration. Ophthalmology. 2010;117(8): 1577-1584.
57. Sayanagi K, Sharma S, Yamamoto T, Kaiser PK. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology. 2009;116(5):947-955.
58. Querques G, Forte R, Berboucha E, et al. Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmic Res. 2011;46(3): 152-159.
59. Spaide RF. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. Am J Ophthalmol. 2009;147(4):644-652.
60. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103(12): 1796-1806.
61. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105(6):998-1003.
62. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464-1474.
63. Gieser JP, Rusin MM, Mori M, Blair NP, Shahidi M. Clinical assessment of the macula by retinal topography and thickness mapping. Am J Ophthalmol. 1997;124(5):648-660.
64. Baumann M, Gentile RC, Liebmann JM, Ritch R. Reproducibility of retinal thickness measurements in normal eyes using optical coherence tomography. Ophthalmic Surg Lasers. 1998;29(4):280-285.
65. Koozekanani D, Roberts C, Katz SE, Herderick EE. Intersession repeatability of macular thickness measurements with the Humphrey 2000 OCT. Invest Ophthalmol Vis Sci. 2000;41(6):1486-1491.
66. Yanoff M, Fine BS, Brucker AJ, Eagle RC. Pathology of human cystoid macular edema. Surv Ophthalmol. 1984;28 Suppl:S505-S511.
67. Fine BS, Brucker AJ. Macular edema and cystoid macular edema. Am J Ophthalmol. 1981;92(4):466-481.
68. Tso MO. Pathology of cystoid macular edema. Ophthalmology. 1982; 89(8):902-915.
69. Schuman JS, Pedut-Kloizman T, Hertzmark E, et al. Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography. Ophthalmology. 1996;103(11):1889-1898.
70. Punjabi OS, Flynn HW Jr, Knighton RW, et al. Spectral domain optical coherence tomography for proliferative diabetic retinopathy with subhyaloid hemorrhage. Ophthalmic Surg Lasers Imaging. 2008;39(6): 494-496.
71. Kroll P, Wiegand W, Schmidt J. Vitreopapillary traction in proliferative diabetic vitreoretinopathy [see comments]. Br J Ophthalmol. 1999;83(3):261-264.
72. Kitaya N, Nagaoka T, Hikichi T, et al. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol. 2003;87(6):709-712.
73. Montero JA, Ruiz-Moreno JM. Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy. Br J Ophthalmol. 2005;89(5):562-564.
74. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967;63(3):Suppl:S1-S139.
75. Spaide RF, Goldbaum M, Wong DW, Tang KC, Iida T. Serous detachment of the retina. Retina. 2003;23(6):820-846; quiz 895.
76. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol. 1994;112(8):1057-1062.
77. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103(12):2070-2079; discussion 2079-2080.
78. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina. 1999;19(6):508-512.
79. Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996;121(1):26-34.
80. Giovannini A, Scassellati-Sforzolini B, D'Altobrando E, Mariotti C, Rutili T, Tittarelli R. Choroidal findings in the course of idiopathic serous pigment epithelium detachment detected by indocyanine green videoangiography. Retina. 1997;17(4):286-293.
81. Hirami Y, Tsujikawa A, Sasahara M, et al. Alterations of retinal pigment epithelium in central serous chorioretinopathy. Clin Experiment Ophthalmol. 2007;35(3):225-230.
82. Fujimoto H, Gomi F, Wakabayashi T, Sawa M, Tsujikawa M, Tano Y. Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography. Ophthalmology. 2008;115(9):1494-1500, 1500. e1.
83. Wang GH, Zhang J, Zhang D, Lv FL, Wang LX. Value of three-dimensional optical coherence tomography and fundus photochromy in correlating the fluorescein leaking sites of acute central serous chorioretinopathy. Med Princ Pract. 2011;20(3):283-286.
84. Hee MR, Puliafito CA, Wong C, et al. Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol. 1995;120(1): 65-74.
85. Spaide RF, Koizumi H, Pozzoni MC, Pozonni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146(4):496-500.
86. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009;147(5):811-815.
87. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29(10):1469-1473.
88. Hussain D, Gass JD. Idiopathic central serous chorioretinopathy. Indian J Ophthalmol. 1998;46(3):131-137.
89. Schatz H, Madeira D, Johnson RN, McDonald HR. Central serous chorioretinopathy occurring in patients 60 years of age and older. Ophthalmology. 1992;99(1):63-67.
90. Wang M, Sander B, Lund-Anderson H, Larsen M. Detection of shallow detachments in central serous chorioretinopathy. Acta Ophthalmol Scand. 1999;77(4):402-405.
91. Yanoff M, Fine BS. Ocular Pathology. A Text and Atlas. 3rd ed. Hagerstown, MD: JB Lippincott Co; 1989.
92. Spaide RF, Lee JK, Klancnik JK Jr, Gross NE. Optical coherence tomography of branch retinal vein occlusion. Retina. 2003;23(3): 343-347.
93. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol. 2002;86(2):247-248.
94. Ichibe M, Yoshizawa T, Murakami K, et al. Surgical management of retinal detachment associated with myopic macular hole: anatomic and functional status of the macula. Am J Ophthalmol. 2003;136(2): 277-284.
95. Takano M, Kishi S. Foveal retinoschisis and retinal detachment in severely myopic eyes with posterior staphyloma. Am J Ophthalmol. 1999;128(4):472-476.
96. Wang S, Peng Q, Zhao P. SD-OCT use in myopic retinoschisis pre-and post-vitrectomy. Optom Vis Sci. 2012;89(5):678-683.
97. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96: 557-634.
98. Yonekawa Y, Kim IK. Pseudophakic cystoid macular edema. Curr Opin Ophthalmol. 2012;23(1):26-32.
99. Nikica G, Ljerka HP, Jelena P, Metez-Soldo K, Mladen B. Cystoid macular edema in anterior chamber lens implantation following posterior capsule rupture. Doc Ophthalmol. 1992;81(3):309-315.
100. Gass JDM. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment. 4th ed. St Louis, MO: Mosby; 1997.
101. Shukla D, Gupta SR, Neelakantan N, et al. Type 2 idiopathic macular telangiectasia. Retina. 2012;32(2):265-274.
102. Hayreh SS. Posterior ciliary artery circulation in health and disease: the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2004;45(3):749-757, 748.
103. Fujiwara T, Imamura Y, Margolis R, Slakter JS, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am J Ophthalmol. 2009;148(3):445-450.
104. Dell'Omo R, Costagliola C, Di Salvatore F, Cifariello F, Dell'Omo E. Enhanced depth imaging spectral-domain optical coherence tomography. Retina. 2010;30(2):378-379.
105. Querques G, Lattanzio R, Querques L, et al. Enhanced depth imaging optical coherence tomography in type 2 diabetes. Invest Ophthalmol Vis Sci. 2012;53(10):6017-6024.
106. Reibaldi M, Boscia F, Avitabile T, et al. Enhanced depth imaging optical coherence tomography of the choroid in idiopathic macular hole: A cross-sectional prospective study. Am J Ophthalmol. 2011;151(1): 112-117. e2.
107. Coscas F, Coscas G, Querques G, et al. En face enhanced depth imaging optical coherence tomography of fibrovascular pigment epithelium detachment. Invest Ophthalmol Vis Sci. 2012;53(7):4147-4151.
108. Arevalo JF, Maia M, Garcia-Amaris RA, et al; Pan-American Collaborative Retina Study Group. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology. 2009; 116(8):1481-1487.